Compare DNLI & PGNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNLI | PGNY |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2017 | 2019 |
| Metric | DNLI | PGNY |
|---|---|---|
| Price | $19.97 | $24.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $32.67 | $27.25 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.96 |
| EPS | N/A | ★ 0.62 |
| Revenue | N/A | ★ $1,268,689,000.00 |
| Revenue This Year | N/A | $11.55 |
| Revenue Next Year | $3,993.60 | $9.52 |
| P/E Ratio | ★ N/A | $38.96 |
| Revenue Growth | N/A | ★ 11.41 |
| 52 Week Low | $10.57 | $13.86 |
| 52 Week High | $26.18 | $27.51 |
| Indicator | DNLI | PGNY |
|---|---|---|
| Relative Strength Index (RSI) | 66.94 | 50.97 |
| Support Level | $17.65 | $23.75 |
| Resistance Level | $19.63 | $27.51 |
| Average True Range (ATR) | 0.97 | 0.98 |
| MACD | 0.15 | -0.33 |
| Stochastic Oscillator | 84.57 | 7.58 |
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.